Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

The National Institute for Health and Care Excellence (NICE) invited the manufacturer (Roche) of pralsetinib (Gavreto(®)), as part of the single technology appraisal (STA) process, to submit evidence for the clinical effectiveness and cost effectiveness of pralsetinib for the treatment of adult pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Khayat, Mohamed N. M. T., Armstrong, Nigel, Howick, Jeremy, O’Meara, Susan, Posadzki, Pawel, Ryder, Steve, Ahmadu, Charlotte, Konings, Stefan R. A., Postma, Maarten J., Duffy, Steven, Wolff, Robert F., van Asselt, Antoinette D. I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020319/
https://www.ncbi.nlm.nih.gov/pubmed/36757608
http://dx.doi.org/10.1007/s40273-023-01247-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020319/
https://www.ncbi.nlm.nih.gov/pubmed/36757608
http://dx.doi.org/10.1007/s40273-023-01247-w

Ejemplares similares